1392150-82-1

Basic information

• Product Name: tert-butyl 2-amino-4-(1-methylpiperidin-4-yl)benzoate
• Synonyms: tert-butyl 2-amino-4-(1-methylpiperidin-4-yl)benzoate
• CAS NO: 1392150-82-1
• Molecular Weight: 290.406
• Mol File: 1392150-82-1.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: tert-butyl 2-amino-4-(1-methylpiperidin-4-yl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 2-amino-4-(1-methylpiperidin-4-yl)benzoate(1392150-82-1)
• EPA Substance Registry System: tert-butyl 2-amino-4-(1-methylpiperidin-4-yl)benzoate(1392150-82-1)

Safety Data

• Hazardous Substances Data: 1392150-82-1(Hazardous Substances Data)

Upstream product

• 1392150-80-9 tert-butyl 2-nitro-4-(pyridin-4-yl)benzoate 
• 1392150-81-0 4-(4-(tert-butoxycarbonyl)-3-nitrophenyl)-1-methylpyridin-1-ium iodide 
• 890315-72-7 tert-butyl 4-bromo-2-nitrobenzoate 
• 1692-15-5 4-pyridylboronic acid 

Downstream Products

• 1392150-83-2 tert-butyl 4-(1-methylpiperidin-4-yl)-2-((tetrahydro-2H-pyran-4-yl)amino)benzoate 
• 1392150-79-6 4-(1-methylpiperidin-4-yl)-2-(2,2,2-trifluoro-N-(tetrahvdro-2H-pyran-4-yl)acetamido)benzoic acid trifluoroacetic acid salt 

Relevant articles and documents

BENZO- AND PYRIDO-PYRAZOLES AS PROTEIN KINASE INHIBITORS

The invention relates to new chemical compounds of Formula (I), pharmaceutical compositions containing them, and their use for the pharmacological treatment of a cancer, preferably a glioblastoma.

DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING PAIN

The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; for use in the treatment of pain.

Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk

The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture, as well as pharmaceutical composition comprising such a compound, for use in the treatment of a cancer associated with the overexpression of at least one Trk protein.